A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
about
Recent developments and future prospects in the treatment of visceral leishmaniasisIdentification of new antileishmanial leads from hits obtained by high-throughput screeningTropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model.In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Drug delivery: lessons to be learnt from Leishmania studies.Investigational drugs for visceral leishmaniasis.Design of amphotericin B oral formulation for antifungal therapy.Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapyEfficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasisReview and analysis of FDA approved drugs using lipid-based formulations.Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats.Leishmaniasis in humans: drug or vaccine therapy?The oral delivery of amphotericin B
P2860
Q26740563-65B5F050-DEF7-45D4-9961-71A2D204EC64Q28481400-73957B0D-F115-4DF6-9AC6-1BA78FDCF873Q35184189-785D0E92-B200-4010-BF46-5F022D86F71EQ35213783-F7A4C2C6-C80C-40B6-B570-17BF5CDB4926Q36868273-E3109D5A-D987-41CE-921A-44CED58B9B34Q38254087-664BAD45-44DB-4241-A587-4A7DF0E1B169Q38269581-3FB2A353-56B9-4915-AF84-AFB226AB8087Q38762337-7A5F8A56-4466-4DC6-8A54-829EA5D4175FQ38892819-F07B86DA-23DE-41FA-A51C-4DC508FD36D9Q39091841-2C642EC7-E014-449B-A884-0C6AA05979D0Q39411779-126C51F4-5193-4DA3-A050-0F3D39567B7DQ39579669-B4091C4D-A26B-4385-93AD-ADF7DF04B263Q40099567-2D180487-DD08-45DE-9E8F-EEFEB56E508AQ45850524-A619F281-4BA3-4029-8F17-097FB04549C8Q47556262-026236B6-8B9E-4B5C-BD7D-C05F1AF4A9A5Q57610422-5C8A118D-A848-466E-8C09-22A179FEB41D
P2860
A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A novel tropically stable oral ...... ishmaniasis in a murine model.
@ast
A novel tropically stable oral ...... ishmaniasis in a murine model.
@en
type
label
A novel tropically stable oral ...... ishmaniasis in a murine model.
@ast
A novel tropically stable oral ...... ishmaniasis in a murine model.
@en
prefLabel
A novel tropically stable oral ...... ishmaniasis in a murine model.
@ast
A novel tropically stable oral ...... ishmaniasis in a murine model.
@en
P2093
P2860
P1476
A novel tropically stable oral ...... eishmaniasis in a murine model
@en
P2093
Ellen K Wasan
Jinying Zhao
John G Clement
Karl Werbovetz
Kishor M Wasan
Richard R Tidwell
Sheila J Thornton
Xiaohua Zhu
P2860
P356
10.1371/JOURNAL.PNTD.0000913
P407
P577
2010-12-07T00:00:00Z